Law360, New York (August 21, 2009) -- A federal appeals court has rejected a bid for an en banc rehearing of its decision to limit a settlement to $10 million in a class action alleging that Abbott Laboratories illegally jacked up the prices of its market-dominating HIV drug Norvir, sticking to its finding that the plaintiffs failed to state a claim in light of recent case law.
The U.S. Court of Appeals for the Ninth Circuit on Wednesday unanimously denied the plaintiffs' petition for rehearing. The petition for rehearing en banc was circulated to the judges of...
